

**VASCULAR BIOLOGY, ATHEROSCLEROSIS, AND ENDOTHELIUM BIOLOGY****Chitinase Inhibition Promotes Atherosclerosis in Hyperlipidemic Mice**Shiro Kitamoto,<sup>\*†</sup> Kensuke Egashira,<sup>†‡</sup> Toshihiro Ichiki,<sup>†</sup> Xinbing Han,<sup>\*</sup> Sara McCurdy,<sup>§</sup> Shohei Sakuda,<sup>¶</sup> Kenji Sunagawa,<sup>‡</sup> and William A. Boisvert<sup>\*§</sup>

From the Department of Medicine,<sup>\*</sup> Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; the Departments of Cardiovascular Medicine<sup>†</sup> and Advanced Therapeutics for Cardiovascular Diseases,<sup>‡</sup> Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; the Center for Cardiovascular Research,<sup>§</sup> University of Hawaii, John A. Burns School of Medicine, Honolulu, Hawaii; and the Department of Applied Biological Chemistry,<sup>¶</sup> The University of Tokyo, Tokyo, Japan

Accepted for publication  
April 1, 2013.

Address correspondence to  
William A. Boisvert, Ph.D.,  
Center for Cardiovascular  
Research, University of Hawaii,  
John A. Burns School of  
Medicine, 651 Ilalo St, BSB  
311C, Honolulu, HI 96813; or  
Shiro Kitamoto, M.D., Ph.D.,  
Department of Advanced Ther-  
apeutics for Cardiovascular  
Diseases, Kyushu University,  
Graduate School of Medical  
Sciences, 3-1-1 Maidashi  
Higashi-ku, Fukuoka, Japan  
812-8582. E-mail: [wab@hawaii.edu](mailto:wab@hawaii.edu) or [shiro\\_kt@cardiol.med.kyushu-u.ac.jp](mailto:shiro_kt@cardiol.med.kyushu-u.ac.jp).

Chitinase 1 (CHIT1) is secreted by activated macrophages. Chitinase activity is raised in atherosclerotic patient sera and is present in atherosclerotic plaque. However, the role of CHIT1 in atherosclerosis is unknown. Preliminary studies of atherosclerosis in cynomolgous monkeys revealed CHIT1 to be closely correlated with areas of macrophage infiltration. Thus, we investigated the effects of a chitinase inhibitor, allosamidin, on macrophage function *in vitro* and on atherosclerotic development *in vivo*. In RAW264.7 cells, allosamidin elevated monocyte chemoattractant protein 1 and tumor necrosis factor alpha expression, and increased activator protein 1 and nuclear factor- $\kappa$ B transcriptional activity. Although inducible nitric oxide synthase, IL-6, and IL-1 $\beta$  expression were increased, Arg1 expression was decreased by chitinase inhibition, suggesting that suppression of CHIT1 activity polarizes macrophages into a M1 phenotype. Allosamidin decreased scavenger receptor AI, CD36, ABCA1, and ABCG1 expression which led to suppression of cholesterol uptake and apolipoprotein AI-mediated cholesterol efflux in macrophages. These effects were confirmed with CHIT1 siRNA transfection and CHIT1 plasmid transfection experiments in primary macrophages. Apolipoprotein E-deficient hyperlipidemic mice treated for 6 weeks with constant administration of allosamidin and fed an atherogenic diet showed aggravated atherosclerotic lesion formation. These data suggest that CHIT1 exerts protective effects against atherosclerosis by suppressing inflammatory responses and polarizing macrophages toward an M2 phenotype, and promoting lipid uptake and cholesterol efflux in macrophages. (*Am J Pathol* 2013, 183: 313–325; <http://dx.doi.org/10.1016/j.ajpath.2013.04.003>)

Atherosclerosis is characterized by excessive lipid accumulation and chronic inflammation within the arterial wall.<sup>1</sup> When risk factors such as hyperlipidemia and hypertension are presented, vascular endothelial cells are stimulated to express adhesion molecules, which promote attachment of circulating leukocytes. Concomitantly, increased endothelial permeability allows deposition of cholesterol-containing lipoproteins in the intima. These lipoproteins can become biologically or chemically modified and stimulate surrounding cells to express chemokines such as monocyte chemoattractant protein 1 (MCP-1), which can induce further leukocyte migration into the vascular wall. Monocytes are one of the first leukocytes to transmigrate and differentiate into macrophages, which are the predominant immune cells observed in atherosclerotic lesions, especially in the early stages. Macrophages possess an

unlimited propensity to take up accumulated modified lipoproteins such as oxidized low density lipoprotein via scavenger receptors (SR) and thereby get transformed into cholesterol-rich foam cells that make up the majority of the

Supported by a Grant-in-Aid for Young Scientists (17102) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and funds from the Takeda Science Foundation, Osaka, Japan (S.K.), by Grants-in-Aid for Scientific Research (14657172 and 14207036) from the Ministry of Education, Culture, Sports, Science, and Technology, Tokyo, Japan (K.E.), Health Science Research Grants (Comprehensive Research on Aging and Health, and on Translational Research) from the Ministry of Health Labor and Welfare, Tokyo, Japan (K.E.), and the Program for Promotion of Fundamental Studies in Health Sciences of the Organization for Pharmaceutical Safety and Research, Tokyo, Japan (K.E.), by grants from the NIH (R01HL075677 and R01HL081863), and by a grant from the Hawaii Community Foundation (10ADVC-47037) (W.A.B.).

early fatty streaks. Macrophages activated by modified lipoproteins produce pro-inflammatory cytokines, including IL-1 $\beta$  and tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), which can mediate inflammation in the arterial wall and cause subsequent infiltration of T lymphocytes that may further accelerate inflammation in the lesion. Activated macrophages also produce reactive oxygen species, matrix metalloproteinases that degrade extracellular matrix, and the procoagulant tissue factor, which induce subsequent plaque rupture and thrombogenesis.<sup>2</sup> Thus, macrophages play a pivotal role in the pathogenesis of lesion formation throughout all stages of atherosclerosis.

The enzyme chitinase [chitinase 1 (CHIT1)] is a member of the glycosyl hydrolase family 18, which cleaves its substrate, chitin.<sup>3</sup> Chitin is a polymer of  $\beta$ -1,4-N-acetyl-glucosamine, which is produced by many living organisms including insects, fungi, crustaceans, and other marine organisms. Interestingly, despite the absence of chitin in mammals, CHIT1 is abundantly produced by activated macrophages in various human diseases, including Gaucher disease and Niemann-Pick disease. It has also been reported that chitinase activity is elevated up to 55-fold in human atherosclerotic tissue.<sup>4</sup> Moreover, serum chitinase activity is elevated in patients with atherosclerosis and is associated with the severity of atherosclerotic lesions.<sup>5</sup> Similarly, when we performed a comprehensive gene expression analysis by DNA microarray assay, we found a tight correlation between CHIT1 mRNA expression and areas of macrophage infiltration in atherosclerotic lesions of cynomolgus monkeys. However, little is known about the physiological role of CHIT1 in the pathogenesis of atherosclerosis. In this study, we investigated the effects of a chitinase inhibitor, allosamidin,<sup>6</sup> on macrophage function and atherosclerotic lesion development to speculate how CHIT1 activity might function in atherosclerosis.

## Materials and Methods

### Cell Culture

The mouse macrophage cell line RAW264.7 (American Type Culture Collection, Rockville, MD) was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, penicillin (50 U/mL), streptomycin (50  $\mu$ g/mL), and L-glutamine (2 mmol/L). Cells were kept at subconfluence in a humidified incubator at 37°C with 5% CO<sub>2</sub>. RAW264.7 cells were treated with 10  $\mu$ mol/L allosamidin to inhibit chitinase activity. Bone marrow-derived macrophages (BMDM) from C57BL/6 mice were generated by flushing the femurs of mice.<sup>7</sup> After centrifugation at 300  $\times$  g, the cells were resuspended in macrophage growth medium consisting of DMEM and 10% fetal bovine serum, and were supplemented with 20% (v/v) L929 cell conditioned medium as a source of colony-stimulating factor, penicillin (100 U/mL) and streptomycin (100 mg/mL). Fibroblasts were allowed to adhere for 4

hours at 37°C and then nonadherent cells were transferred to another flask. This step was repeated after overnight incubation at 37°C. On day 8, most of the adherent cells were macrophages (>98% MAC1-positive cells and 99% phagocytosis activity). Isolated BMDM were stimulated with acetylated low density lipoprotein (Ac-LDL, 50  $\mu$ g/mL) (Life Technologies, Grand Island, NY); monocyte chemoattractant protein-1 (MCP-1, 100 ng/mL, R&D Systems, Minneapolis, MN); lipopolysaccharide (LPS, 100 ng/mL) (Sigma-Aldrich, St. Louis, MO); advanced glycation end product bovine serum albumin (AGE-BSA, 100  $\mu$ g/mL, Calbiochem, La Jolla, CA); or interferon gamma (IFN $\gamma$ ) (100 units/mL, eBioscience, San Diego, CA). The cells were also treated with 20  $\mu$ mol/L allosamidin or vehicle control  $\pm$  10 units/mL IFN- $\gamma$ , and used for the CHIT1 plasmid transfection study. Thioglycollate-elicited peritoneal macrophages were obtained from male C57BL/6 mice by standard method. In brief, mice were injected intraperitoneally with 1 mL of 3% Brewer thioglycollate medium (Becton Dickinson, Franklin Lakes, NJ). Four days later, the peritoneal cells were harvested by lavage with cold PBS and plated on petri dishes. The cells were allowed to adhere for 4 hours and washed with PBS to remove nonadherent cells before being used for the siRNA transfection study.

### Chitinase Activity Assay

Chitinase activity assay was performed using 4-methylumbelliferyl-N, N', N''-triacyetyl chitotrioside [4MU-(GlcNAc)<sub>3</sub>] (Sigma-Aldrich, St. Louis, MO) as a substrate.<sup>8</sup> A solution of 25  $\mu$ mol/L 4MU-(GlcNAc)<sub>3</sub> in N, N-dimethylformamide was diluted 1:500 with distilled water, and the resulting solution (40  $\mu$ L) was added to 0.5, 2, or 4  $\mu$ L mixture of the culture filtrate in each experiment along with 50 mmol/L citric acid (50 mmol/L Na<sub>2</sub>HPO<sub>4</sub> buffer; pH 5.0; 100  $\mu$ L). After incubating the mixture at 28.5°C for 60 minutes, the reaction was stopped by adding 1.0 M glycine (NaOH buffer; pH 10.5; 2.5 mL), and the liberated 4-methylumbelliferone was measured with a fluorescence spectrometer (excitation at 360 nm, emission at 450 nm). The value of fluorescence strength was used for calibration of relative chitinase activity or calculation of absolute chitinase activity (U/mL) by referring to standard 4-methylumbelliferone solution. [Unit definition: One unit will release 1.0  $\mu$ mole of 4-methylumbelliferone from 4MU-(GlcNAc)<sub>3</sub> per minute].

### RNA Extraction and Real-Time RT-qPCR

Total cellular RNA was extracted from cells using TRIzol (Invitrogen, San Diego, CA), according to the recommended procedure. Real-time quantitative RT-PCR (real-time RT-qPCR) was performed using the ABI Prism 7700 (Applied Biosystems, Foster City, CA) SYBR Green analysis. The sequence-specified PCR primers used in these experiments

**Table 1** Sequence-Specific PCR Primers Used for Real-Time RT-qPCR

Gene name	Primers
<i>GAPDH</i>	Forward 5'-GGCAAATTC AACGGC CACAGT-3' Reverse 5'-CGCTCCTGGAAGATGGTGAT-3'
<i>CHIT1</i>	Forward 5'-CGTCATCTTTGCTTTTGCTGG-3' Reverse 5'-TGGTAGAGAAGTTCGTCATTGTGC-3'
<i>MCP-1</i>	Forward 5'-TCACTGAAGCCAGCTCTCTCT-3' Reverse 5'-GTGGGGCGTTAACTGCAT-3'
<i>TNF<math>\alpha</math></i>	Forward 5'-CTGTAGCCCACGTCGTAG C-3' Reverse 5'-GGTTGTCTTTGAGATCCATGC-3'
<i>CCR2</i>	Forward 5'-AGCACATGTGGTGAATCCAA-3' Reverse 5'-TGCCATCATAAAGGAGCCA-3'
<i>CD36</i>	Forward 5'-CAAGTCCTTGGCATGGTAGA-3' Reverse 5'-TGGATTTGCAAGCACAAATATGAA-3'
<i>SR-AI</i>	Forward 5'-TTAAAGGTGATCGGGGACAAA-3' Reverse 5'-CAACCAGTCGAACCTGTCTTAAG-3'
<i>ABCA1</i>	Forward 5'-CCCAGAGCAAAAAGCGACTC-3' Reverse 5'-GGTCATCATCACTTTGGTCTTG-3'
<i>ABCG1</i>	Forward 5'-CAAGACCCTTTTGAAAGGGATCTC-3' Reverse 5'-GCCAGAATATTCATGAGTGTGGAC-3'
<i>PPAR<math>\gamma</math></i>	Forward 5'-GTCACGTTCTGACAGGACTGTGTGAC-3' Reverse 5'-TATCACTGGAGATCTCCGCCAACAGC-3'
<i>LXR<math>\alpha</math></i>	Forward 5'-AGGAGTGTCGACTTCCGAAA-3' Reverse 5'-CTCTTCTTGCCGCTTCAGTTT-3'
<i>iNOS</i>	Forward 5'-CAAGCTGAACCTTGAGCGAGGA-3' Reverse 5'-TTTACTCAGTGCCAGAAGCTGGA-3'
<i>IL-6</i>	Forward 5'-CCACTCACAAGTCGGAGGCTTA-3' Reverse 5'-GCAAGTGCATCATCGTTGTTTCATAC-3'
<i>IL-12p35</i>	Forward 5'-TGTCTTAGCCAGTCCCAGAAACC-3' Reverse 5'-TCTTCATGATCGATGTCTTCAGCAG-3'
<i>IL-1<math>\beta</math></i>	Forward 5'-TCCAGGATGAGGACATGAGCAC-3' Reverse 5'-GAACGTCACACACCAGCAGGTTA-3'
<i>Arg1</i>	Forward 5'-AGCTCTGGGAATCTGCATGG-3' Reverse 5'-ATGTACACGATGTCTTTGGCAGATA-3'
<i>FIZZ1</i>	Forward 5'-TCCAGCTGATGGTCCCAGTG-3' Reverse 5'-GAGGCCATCTGTTTCATAGTCTTG-3'
<i>IL-10</i>	Forward 5'-GACCAGCTGGACAACATACTGCTAA-3' Reverse 5'-GATAAGGCTTGGCAACCCAAGTAA-3'

*ABCA1*, ATP-binding cassette transporter A1; *GAPDH*, glyceraldehyde-3-phosphate dehydrogenase; *iNOS*, inducible nitric oxide synthase; *LXR $\alpha$* , liver X receptor  $\alpha$ ; *PPAR $\gamma$* , peroxisome proliferator-activated receptor  $\gamma$ ; *SR-AI*, scavenger receptor AI.

are listed in Table 1. The gene products were quantified using SYBR Green assays (Applied Biosystems, Foster City, CA) and glyceraldehyde-3-phosphate dehydrogenase was used for normalization.

### Electromobility Shift Assay

Cells were cultured on a 12-well plate overnight. For collection of nuclear protein, cells were rinsed with PBS, removed from the plate with a cell scraper, transferred to a microfuge tube, and centrifuged at 4000 rpm for 5 minutes. The cell pellets were resuspended in 400  $\mu$ L of cold 1 $\times$  Solution A buffer [10 mmol/L HEPES (pH 7.4), 10 mmol/L KCl, 1.5 mmol/L MgCl<sub>2</sub>, 0.5 mmol/L dithiothreitol, 0.4 mmol/L phenylmethylsulfonyl fluoride]. After resuspension, samples were incubated for 20 minutes on ice and vortexed

for 1 minute. Samples were centrifuged at 600  $\times$  g for 10 minutes, and supernatant was completely removed. Pellets were resuspended in 1 mL of Solution C buffer containing 20 mmol/L HEPES (pH 7.4), 0.42 mmol/L NaCl, 1.5 mmol/L MgCl<sub>2</sub>, 0.5 mmol/L dithiothreitol, 0.4 mmol/L phenylmethylsulfonyl fluoride and were placed on ice for 20 minutes. Samples were spun at 13,000 rpm for 10 minutes, and supernatants were transferred to a fresh tube. Protein concentration was determined using the bicinchoninic acid (BCA) Protein Assay Kit (Pierce, Rockford, IL) per the manufacturer's directions. Nuclear factor- $\kappa$ B (NF- $\kappa$ B) and activator protein 1 (AP-1) consensus oligomer (50 ng) (Santa Cruz Biotechnology, Santa Cruz, CA) were labeled with [ $\gamma$ -<sup>32</sup>P] ATP using T4 polynucleotide kinase (TAKARA BIO INC, Ohtsu, Japan). The sequence of each consensus oligomer is described as follows. Nuclear protein (5  $\mu$ g) was reacted with 20,000 cpm of labeled oligomer in binding buffer containing 20 mmol/L HEPES, 60 mmol/L KCl, 4% Ficoll, 0.1 mg/mL bovine serum albumin (BSA), 2 mmol/L dithiothreitol, and 0.1 mg/mL poly(dI-dC) (Roche, Basel, Switzerland) on ice for 30 minutes and was analyzed on a 6% acrylamide gel (80:1 ratio of acrylamide to bis-acrylamide). Gels were dried and exposed to X-ray film (Amersham, Arlington Heights, IL). For cold competition, 100-fold excess of unlabeled oligomer was added. The sequence of each consensus oligomer was: NF- $\kappa$ B: 5'-AGTTGAGGG-GACTTTCCAGGC-3' and AP-1: 5'-CGCTTGATGACT-CAGCCGGAA-3'.

### Reporter Gene Assay

2  $\times$  10<sup>5</sup> RAW264.7 cells were prepared in a 24-well plate. The cells were then transfected with 0.7  $\mu$ g/well of AP-1 or NF- $\kappa$ B promoter-luciferase plasmid (Clontech) and 0.3  $\mu$ g per well of  $\beta$ -galactosidase gene driven by SV40 promoter-enhancer sequence (Promega). The transfection was performed using SuperFect transfection reagent according to the manufacturer's instructions (Qiagen, Valencia, CA). After incubation for 24 hours, cells were treated with 10  $\mu$ mol/L of allosamidin or control vehicle for 6 hours. The cells were washed twice with phosphate-buffered saline, lysed in 200  $\mu$ L lysis buffer (25 mmol/L Tris, pH 7.8, 2 mmol/L EDTA, 2 mmol/L DL-dithiothreitol, 10% glycerol, and 1% Triton X-100), and 100  $\mu$ L of lysate was used for luciferase activity assay in a Lumat luminometer (LB 9501) (Berthold Technologies, Oak Ridge, TN). The assay was started by adding 100  $\mu$ L of 470 mmol/L luciferin to cell lysate, and integrated peak luminescence was determined over a 55-second window after a 5-second delay. The  $\beta$ -galactosidase activity in the same sample was measured spectrophotometrically and used to normalize the luciferase activity.

### Binding and Uptake of AcLDL

To determine the receptor-specific binding and uptake, fluorescence-labeled acetylated LDL (DiI-AcLDL) was used

as previously described.<sup>9</sup> Cells seeded in a 12-well plate or chamber slide were treated with allosamidin overnight followed by incubation with DiI-AcLDL at 10  $\mu\text{g}/\text{mL}$  in medium for 2 hours at 37°C. The media containing DiI-AcLDL was removed from culture and the cells were washed twice with probe-free media. Cells from 12-well plate were analyzed using a FACScan flow cytometer (Becton Dickinson), and data were analyzed with the CellQuest Pro version 5.1 (Becton Dickinson). Cells on the chamber slides were observed under fluorescence microscope.

### Cholesterol Efflux Assay

RAW264.7 cells were seeded in a 24-well plate for incubation overnight before being labeled with loading media [DMEM/glutamine/p/s/10% lipoprotein-deficient calf serum 1  $\mu\text{Ci}/\mu\text{L}$  (of [<sup>3</sup>H] cholesterol)] with or without 10  $\mu\text{mol}/\text{L}$  allosamidin for 36 hours. The cells were washed twice with PBS, after which DMEM/glutamine/0.2% fatty acid-free BSA  $\pm$  10  $\mu\text{mol}/\text{L}$  allosamidin was added into each well and incubated for 1 to 2 hours. The medium was then aspirated. For apolipoprotein AI (apoAI) and high-density lipoprotein (HDL)-independent cholesterol efflux assay, efflux medium (DMEM/glutamine/0.2% fatty acid-free BSA,  $\pm$  10  $\mu\text{mol}/\text{L}$  allosamidin) without apoAI and HDL was added to one set of wells. For apoAI or HDL-dependent cholesterol efflux assay, efflux medium, as previously mentioned, along with 20  $\mu\text{g}/\text{mL}$  of apoAI or 50  $\mu\text{g}/\text{mL}$  of HDL was added in another set of wells. After incubation for 2 hours, 100  $\mu\text{L}$  of media was removed and transferred to 1.5 mL Eppendorf tube. Cell debris was spun down by centrifuging for 5 minutes. The supernatant was gently transferred to 5 mL counting fluid to measure radioactivity [as effluxed cholesterol (5-minute program)]. At the end of the experiment, 0.5 mL of 0.1 N NaOH was added to lyse the cells by incubating for 5 hours at room temperature, and 100  $\mu\text{L}$  of cell lysate was transferred to 5 mL counting fluid to measure radioactivity. ApoAI or HDL-induced [<sup>3</sup>H] cholesterol efflux was measured as the fraction of total radiolabeled cholesterol appearing in the medium in the presence of apoAI or HDL after subtraction of values for apoAI and HDL-free medium. ApoAI or HDL-mediated efflux was determined using the following formula: i) percentage of efflux = efflux/total labeled cholesterol; ii) apoAI or HDL specific efflux = percentage of efflux (with apoAI or HDL) – the percentage of efflux (without apoAI and HDL); and iii) percentage of increase in apoAI or HDL-mediated efflux = percentage (apoAI or HDL-specific efflux)/percentage of efflux (without apoAI and HDL).

### siRNA Transfection

Thioglycollate-elicited peritoneal macrophages were transfected with Dharmacon siGENOME SMARTpool siRNA (Thermo Fisher Scientific, Fife, WA) against mouse CHIT1 or siGENOME nontargeting siRNA pool using lipofectamine siRNAMax (Invitrogen), according to the manufacturer's

instructions (final RNA interference duplex concentration, 20 nmol/L). After 48 hours of transfection, the cells were harvested for mRNA extraction and real-time RT-qPCR was performed.

### CHIT1 Gene Transfection

Total mRNA was extracted from the mouse tongue using TRIzol, and mouse CHIT1 cDNA was amplified by using real-time PCR using two primers specific for the mouse *Chit1* gene (the sense primer: 5'-ACAGAGCTGATA-TCCCCAGAGCCT-3'; the antisense primer: 5'-TGGA-GTTGGATGGGGTTCCAGG-3'). The cDNA fragment was cloned into the pTAC-2 TA cloning vector (BioDynamics, Tokyo, Japan) and was further subcloned into the eukaryotic expression vector pcDNA3.1 plasmid. Afterward, BMDM were transfected with control pcDNA3.1 or pcDNA3.1-CHIT1 plasmid using MicroPorator MP-100 (Digital Bio Technology Co., Ltd., Seoul, Korea) according to the manufacturer's instructions. In brief, the cells were resuspended in Neon resuspension buffer R (Invitrogen) containing pcDNA3.1 or pcDNA3.1-CHIT1 plasmid (6 million cells per DNA, 8 mg/100  $\mu\text{L}$ ) and were pulsed twice with a voltage of 800 V and a width of 50 msec using a 100  $\mu\text{L}$  Neon tip (Invitrogen). The cells were then quickly transferred into two 6 cm cell culture plates containing DMEM supplemented with 10% fetal bovine serum. After 48 hours of transfection, the cells were stimulated with or without 10 units/mL IFN- $\gamma$  for 6 hours and harvested for mRNA extraction, and real-time RT-qPCR was performed.

### Animal Models

Ten week old male apolipoprotein E (*ApoE*)-knockout mice (Jackson Laboratory, Bar Harbor, ME) were fed a chow diet or a high fat diet containing 35% (w/w) fat and 1% cholesterol (KBT Oriental Co., Ltd., Tosu, Saga, Japan) with 1.9 mg/kg per day infusion of angiotensin II by osmotic mini pump model 2004 (ALZET, Cupertino, CA) for 4 weeks, and the descending aortas were harvested. Total mRNA was extracted from the aortas and CHIT1 mRNA expression was evaluated by real-time RT-qPCR.

For the atherosclerotic mouse model of CHIT1 inhibition, spontaneous hyperlipidemic C57BL/6.KOR/Stm Slc-*ApoE*<sup>shl</sup> mice, deficient in ApoE expression, were obtained from Japan SLC Inc. (Shizuoka, Japan).<sup>10</sup> Mice (12-weeks-old) were implanted subcutaneously with osmotic mini pump model 2006 (ALZET) containing 10 mg/kg per day allosamidin in 0.1 N acetic acid or 0.1 N acetic acid as a control vehicle, and given the Western diet containing 40% w/w fat and 0.15% cholesterol (KBT Oriental Co, Ltd.) for 6 weeks. Blood was taken every 3 weeks for lipid analysis and chitinase activity measurement in circulation. Systolic blood pressure and heart rate were evaluated by the tail-cuff method. The mice were maintained in the animal facilities at Kyushu University. The

study protocol was reviewed and approved by the Committee on the Ethics of Animal Experiments at Kyushu University Graduate School of Medical Sciences.

### Analysis of Atherosclerosis and Other Measurements in Plasma

Mice were euthanized after 6 weeks of Western diet and perfused via the left ventricle with 10 mL PBS ( $n = 6$  per group). The heart and aortic tree were dissected. Aortic roots were fixed in 4% paraformaldehyde and 5% sucrose, and embedded in OCT compound. The aortas were fixed in 10% formaldehyde overnight. Atherosclerotic lesions of the aortic sinus, as well as the entire length of the aorta, were analyzed as previously described.<sup>11</sup> Frozen sections (6  $\mu$ g) of the aortic sinus were prepared, and the sections were used for detecting lipid (0.5% Oil Red O; Sigma-Aldrich), macrophages (mac-3, 1:1000; Pharmingen, San Diego, CA), and T cells (CD4, 1:100; Pharmingen) in the lesion. The atherosclerotic lesion stained with Oil Red O was quantitated using a computer-assisted imaging system (ImageJ version 1.41; NIH, Bethesda, MD). Lesion cell contents were determined by measuring the absolute positive area (macrophages) in the aortic sinus, or by counting the cells (T cells) in the intimal lesions. The plasma samples collected from the dorsal pedal vein of the mice were used to measure plasma total cholesterol and triglyceride levels to see whether allosamidin had an effect on these circulating lipids, as well as for plasma chitinase activity.

### Statistical Analysis

Results are given as means  $\pm$  SEM. Statistical analysis was performed by unpaired Student's *t*-test and one-way analysis of variance in comparing the differences between two groups and among multiple groups, respectively. A *P* value  $< 0.05$  was considered significant.

## Results

### CHIT1 Expression Correlates with Atherosclerotic Lesion Area in Cynomolgous Monkeys

We previously reported that statin or anti-MCP-1 therapy resulted in regression and stabilization of atherosclerotic lesions, independent of cholesterol levels in nonhuman primates.<sup>12</sup> In this experiment, DNA microarray assay was performed with mRNA from atherosclerotic lesions of descending aorta to explore atherosclerosis-related genes, and CHIT1 was found to be one of 11 candidate genes that were closely correlated with treatment with pravastatin and 7ND transfection. Real-time PCR results confirmed that CHIT1 mRNA expression was reduced in pravastatin or 7ND-treated group (Supplemental Figure S1A). Furthermore, CHIT1 mRNA expression was also highly correlated

with areas of macrophage infiltration in the atherosclerotic lesions of abdominal aortas (Supplemental Figure S1B).

### CHIT1 Expression Is Upregulated by Pro-Atherosclerotic Stimuli in BMDM


IFN- $\gamma$ , TNF $\alpha$ , and LPS are reported to increase CHIT1 mRNA expression.<sup>13</sup> To examine whether other pro-atherosclerotic stimuli upregulate CHIT1 mRNA expression, BMDM were treated with Ac-LDL, AGE-BSA, MCP-1, LPS, or IFN- $\gamma$ . Although stimulation with Ac-LDL, AGE-BSA, LPS, and IFN- $\gamma$  increased CHIT1 mRNA expression, MCP-1 had no effect on CHIT1 mRNA expression (Figure 1A).

### Chitinase Inhibition Increases Pro-Inflammatory Cytokine Expression in Macrophages and Polarizes Macrophages into a M1 Phenotype

We used allosamidin to inhibit CHIT1 *in vitro* and *in vivo*. Chitinase activity was suppressed by allosamidin in a dose-dependent manner, with 10  $\mu$ mol/L of allosamidin suppressing chitinase activity by more than 90% *in vitro* (Supplemental Figure S2). Because inflammation is one of the most important factors in the pathogenesis of atherosclerosis, we investigated the effects of allosamidin on pro-inflammatory cytokine expression in macrophages. Allosamidin treatment increased MCP-1 and TNF $\alpha$  mRNA expression in RAW264.7 macrophages, but did not change CCR2 expression (Figure 1B). To determine whether these changes were mediated via activation of transcriptional factors, we performed electromobility shift assay and reporter gene assay for AP-1 and NF- $\kappa$ B, and found that transcriptional activities of both AP-1 and NF- $\kappa$ B were modestly increased by allosamidin treatment (Figure 2, A and B). We also investigated whether allosamidin would influence macrophage polarization. Expression of M1 markers, inducible nitric oxide synthase, IL-6, and IL-1 $\beta$ , were increased, whereas expression of a M2 marker, Arg1, was decreased by chitinase inhibition (Figure 1B). Although not statistically significant, allosamidin treatment tended to decrease another M2 marker, Fizz1 expression, but raised IL-10 expression (Figure 1B). Collectively, these trends indicate that CHIT1 in its uninhibited state would favor M2 polarization.

### Allosamidin Decreases Cholesterol Uptake and Efflux in Macrophages

Because lipid-laden macrophages also play an important role in the pathogenesis of atherosclerosis, we investigated the effects of allosamidin on cholesterol metabolism in macrophages. Allosamidin treatment decreased ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1), scavenger receptor AI (SR-AI), and CD36 mRNA expression in RAW264.7 cells (Figure 3A). Peroxisome proliferator-activated receptor  $\gamma$



**Figure 1** **A:** Chitinase activity increased in BMDM treated with Ac-LDL, AGE-BSA, LPS, and IFN- $\gamma$ . BMDM from C57BL/6 mice were isolated and stimulated with 50  $\mu$ g/mL AcLDL, 100 ng/mL MCP-1, 100 ng/mL LPS, 100  $\mu$ g/mL AGE-BSA, or 100 units/mL IFN- $\gamma$ . After 24 hours of stimulation, chitotriosidase activity in the media was measured as described in *Materials and Methods*. **B:** Chitinase inhibitor modifies expression of pro-inflammatory cytokines and polarizes macrophages into M1 phenotype. RAW264.7 macrophages were treated with medium alone or 10  $\mu$ mol/L allosamidin for 24 hours before RNA isolation. Transcripts for TNF $\alpha$ , MCP-1, CCR2, inducible nitric oxide synthase, IL-6, IL-12p35, IL-1 $\beta$ , Arg1, FIZZ1, and IL-10 were quantified by real-time PCR. Results are representative of at least three independent experiments and values are expressed as fold change in abundance (means  $\pm$  SEM). \* $P$  < 0.05, \*\* $P$  < 0.01 versus control.

(PPAR $\gamma$ ) and liver X receptor  $\alpha$  (LXR $\alpha$ ) expressions were also suppressed by allosamidin treatment (Figure 3A). In accordance with these results, allosamidin suppressed receptor-specific binding and uptake of acLDL (Figure 3B). Moreover, cholesterol efflux assay showed that ApoAI-specific cholesterol efflux was significantly decreased by allosamidin treatment (Figure 3C). HDL-specific cholesterol efflux tended to decrease, although not significantly, and the increase in percentage of HDL-specific efflux was significantly reduced by allosamidin treatment (Figure 3C).


### The Effects of Specific CHIT1 Inhibition and CHIT1 Overexpression Resemble that of Allosamidin in Primary Macrophages

To elucidate whether the allosamidin treatment would have similar effects in primary macrophages as in RAW264.7 cells, we treated BMDM with allosamidin  $\pm$  IFN- $\gamma$  stimulation. To inhibit CHIT1 mRNA expression specifically, we also transfected thioglycollate-elicited peritoneal macrophages with siRNA against CHIT1. We used peritoneal macrophages in this experiment because the high CHIT1 expression in BMDM made it difficult to be inhibited by siRNA transfection. CHIT1 mRNA expression was decreased by approximately 60% after CHIT1 siRNA transfection (Supplemental Figure S3A). We also transfected BMDM with pcDNA3.1-CHIT1 plasmid to investigate whether

CHIT1 overexpression would have the opposite effect to allosamidin treatment or CHIT1 siRNA transfection. Chitinase activity was increased by approximately 40% after CHIT1 plasmid transfection (Supplemental Figure S3B). With cytokine/chemokine gene expression, allosamidin treatment had similar effects in BMDM as in RAW264.7 cells, especially when stimulated with IFN- $\gamma$  (Figure 4). Most of the genes related to cholesterol metabolism were also significantly reduced by allosamidin in BMDM (Figure 5). CHIT1 siRNA transfection tended to resemble the effects of allosamidin in cytokine/chemokine gene expression (Figure 4) and significantly reduced ABCA1, ABCG1, PPAR $\gamma$ , and LXR $\alpha$  expression, but CD36 and SR-AI mRNA expression were not changed (Figure 5). Although CHIT1 transfection experiments yielded mostly opposite cytokine/chemokine gene expression results compared to allosamidin treatment (Figure 4), only ABCA1 mRNA expression was significantly increased among the genes related to cholesterol metabolism.

### Allosamidin Treatment Promotes Atherosclerosis in ApoE-Deficient Hyperlipidemic Mice

When we evaluated CHIT1 mRNA expression in the atherosclerotic aortas of ApoE knockout mice, CHIT1 mRNA expression tended to decrease in the mice fed a high-fat diet with angiotensin II infusion compared to the



**Figure 2** Chitinase inhibitor increases AP-1 and NF- $\kappa$ B transcriptional activity. **A:** RAW264.7 macrophages were treated with medium alone or 10  $\mu$ mol/L allosamidin overnight. Nuclear protein was extracted and transcriptional activity of AP-1 and NF- $\kappa$ B were accessed by electromobility shift assay. **B:** RAW264.7 macrophages were transfected with AP-1 or NF- $\kappa$ B promoter–luciferase plasmid and 2  $\mu$ g of  $\beta$ -galactosidase gene driven by SV40 promoter–enhancer sequence. The cells were then treated with medium alone or 10  $\mu$ mol/L allosamidin overnight, and luciferase activity and  $\beta$ -galactosidase were measured. \* $P < 0.05$  versus control.

mice fed a chow diet (Figure 6A). To investigate the role of CHIT1 in the pathogenesis of atherosclerosis, we spontaneously treated hyperlipidemic ApoE-deficient mice with allosamidin, while feeding them the Western diet for 6 weeks. Because allosamidin has been reported to inhibit chitinase activity at doses as low as 1 mg/kg *in vivo*,<sup>14</sup> we treated the mice with 1 mg/kg per day using the Alzet osmotic mini pump model 2006 (ALZET). Plasma chitinase activity was suppressed by approximately 40% during the experiment (data not shown) and just before euthanasia (Figure 6B). There were no significant differences in body weight change, blood pressure, heart rate, and plasma lipid profile between the control and allosamidin-treated group (Table 2 and Supplemental Figure S4). Administration of allosamidin aggravated atherosclerotic lesion area in the aortic arch (Figure 6C). There was very little plaque formation in the rest of the aortas for both groups. The atherosclerotic lesion area and macrophage infiltration area in the aortic sinus were also increased by allosamidin


treatment (Figure 6D). There were very few infiltrated T lymphocytes in the plaque with no statistical difference between the two groups (Figure 6D).

## Discussion

Several studies, including ours, have found that chitinase activity is increased in the sera and plaque tissue of atherosclerosis patients and nonhuman primates.<sup>4,5,15</sup> However, it has not been demonstrated whether there is a correlation between chitinase activity and the pathogenesis of atherosclerosis. Because CHIT1 is abundantly produced by activated macrophages, and because macrophages play an important role in the pathogenesis of atherosclerosis,<sup>1,16</sup> we sought to determine the effects of CHIT1 on macrophage function related to atherosclerosis. We used allosamidin to inhibit chitinase activity and investigated whether allosamidin modulates production of pro-inflammatory cytokines and cholesterol metabolism in macrophages using both cultured cells and an *in vivo* atherosclerosis model. We also inhibited CHIT1 gene expression by CHIT1 siRNA transfection and overexpressed CHIT1 protein by transfection of a CHIT1 expression vector to evaluate the specific role of CHIT1. Our data suggest that CHIT1 regulates atherosclerotic development by mediating: i) pro-inflammatory cytokine productions, ii) macrophage polarization, and iii) cholesterol uptake and efflux in macrophages.


Chitinase activity is reported to be elevated in atherosclerosis patients and is correlated to atherothrombotic stroke and ischemic heart disease.<sup>4,5,15,17,18</sup> Serum chitinase activity is also increased in several human lysosomal lipid storage diseases including Gaucher disease and Niemann-Pick disease. It has been proposed as an indicator of disease severity acting as a biochemical marker of macrophage accumulation and activation.<sup>19–22</sup> In all of these diseases, including atherosclerosis, the common theme is abnormal lipid-laden macrophage accumulation in tissues and robust secretion of CHIT1 protein.<sup>19</sup> CHIT1 mRNA expression is further increased by stimulation with TNF $\alpha$ , IFN- $\gamma$ , and LPS.<sup>13,23</sup> Oxidized low density lipoprotein also upregulates chitinase-3-like protein 1 (gp-39) and CHIT1 in cultured macrophages whereas nonmodified LDL does not.<sup>24</sup> Our results show that Ac-LDL, as well as IFN- $\gamma$  and LPS, increased chitinase activity in BMDM, implicating that lipid accumulation and pro-inflammatory cytokine stimulation may induce upregulation of CHIT1 expression in atherosclerotic lesions. Additionally, AGE-BSA also increased chitinase activity in the current study, indicating that the hyperglycemic state, such as diabetes mellitus, may increase CHIT1 expression as well.

There are two major types of macrophage activation: one that promotes inflammation (referred to as classically activated, or M1), and the other that promotes resolution (referred to as alternatively activated, or M2).<sup>25</sup> An imbalance of their activation status can influence lipid metabolism,




**Figure 3** Chitinase inhibitor modifies expression of genes related to cholesterol metabolism and decreases cholesteryl ester uptake and cholesterol efflux in macrophage. **A:** RAW264.7 macrophages were treated with medium alone or 10  $\mu\text{mol/L}$  allosamidin for 24 hours before RNA isolation. Transcripts for ABCA1, ABCG1, CD36, SR-AI, PPAR $\gamma$ , and LXR $\alpha$  were quantified by real-time PCR. \* $P < 0.05$  versus control. **B:** Chitinase inhibitor lowers cholesteryl ester uptake by RAW264.7 cells. Cells were treated with or without allosamidin overnight followed by incubation of Dil-AcLDL at 10  $\mu\text{g/mL}$  in medium for 2 hours at 37°C. Intensity of fluorescence was determined by either confocal microscopy or flow cytometry. **C:** Chitinase inhibitor decreases apoAI and HDL-mediated cholesterol transport. RAW264.7 cells were labeled with  $^3\text{H}$ -cholesterol for 36 hours in the presence or absence of 10  $\mu\text{mol/L}$  allosamidin. ApoAI- or HDL-dependent or independent cholesterol efflux was measured by incubating [ $^3\text{H}$ ] cholesterol-labeled RAW264.7 cells with or without apoAI or HDL. Radioactivity in the media was determined as a percentage of total radioactivity in the cells and media ( $n = 3$ ; means  $\pm$  SEM). \* $P < 0.05$ , \*\* $P < 0.01$  versus control.






**Figure 4** Chitinase inhibition, CHIT1 inhibition, and CHIT1 overexpression modify pro-inflammatory cytokines and polarize primary macrophages toward a M1 phenotype. BMDM were treated with medium alone or 10  $\mu$ mol/L allosamidin for 24 hours and were stimulated with or without 10 units/mL IFN- $\gamma$  for 6 hours before RNA isolation. Thioglycollate-elicited peritoneal macrophages were transfected with siRNA against mouse CHIT1 or nontargeting siRNA using lipofectamine siRNA maximum. After 48 hours of transfection, the cells were harvested for mRNA isolation. BMDM were also transfected with control pcDNA3.1 or pcDNA3.1-CHIT1 plasmid by electroporation (MicroPorator MP-100). After 48 hours of transfection, the cells were stimulated with or without 10 units/mL IFN- $\gamma$  for 6 hours and harvested for mRNA isolation. Transcripts for TNF $\alpha$ , MCP-1, inducible nitric oxide synthase, IL-6, IL-12p35, IL-1 $\beta$ , Arg1, FIZZ1, and IL-10 were quantified by real-time PCR. The results are representative of at least three independent experiments and values are expressed as fold change in abundance (means  $\pm$  SEM). PM $\phi$ , thioglycollate-elicited peritoneal macrophages. \* $P$  < 0.05, \*\* $P$  < 0.01 versus control.



**Figure 5** Chitinase inhibition, CHIT1 inhibition, and CHIT1 overexpression modify expression of genes related to cholesterol metabolism in primary macrophages. Transcripts for ABCA1, ABCG1, CD36, SR-AI, PPAR $\gamma$ , and LXR $\alpha$  were quantified by real-time PCR. The results are representative of at least three independent experiments and values are expressed as fold change in abundance (means  $\pm$  SEM). PM $\phi$ , thioglycollate-elicited peritoneal macrophages. \* $P$  < 0.05, \*\* $P$  < 0.01 versus control.

inflammatory responses, and plaque stability, and thus can affect the progression and complication of atherosclerosis.<sup>26</sup> Because T helper-2 cytokines, such as IL-10, can shift the balance in favor of M2 macrophages and have beneficial effects on atherosclerosis, M2 polarization is thought to be atheroprotective.<sup>11,25,27–29</sup> Gaucher cells, which display

elevated CHIT1 expression in response to lipid accumulation, resemble anti-inflammatory M2 macrophages.<sup>30</sup> Interestingly, another member of the chitinase family, the acidic mammalian chitinase, is reported to mediate T helper-2-specific, IL-13-induced asthma.<sup>14</sup> Taken together, these findings implicate CHIT1 as a mediator of M2 macrophage



**Figure 6** Chitinase inhibitor reduces atherosclerotic lesions in spontaneous ApoE-deficient hyperlipidemic mice fed a Western diet. **A:** CHIT1 mRNA expression in atherosclerotic aortas of ApoE-deficient mice fed a chow diet or high-fat diet with 1.9 mg/kg per day infusion of angiotensin II for 4 weeks. The descending aortas were harvested and total mRNA was extracted. CHIT1 mRNA expression was evaluated by real-time RT-qPCR ( $n = 7$  in control group;  $n = 8$  in high-fat diet + angiotensin II group; means  $\pm$  SEM). **B:** The 12-week-old mice were implanted with an osmotic mini pump model 2006 (ALZET) containing 10 mg/kg per day allosamidin or control vehicle, and fed a Western diet for 6 weeks. Serum chitinase activity was measured before and after 6 weeks of allosamidin treatment. Allosamidin administration suppressed serum chitinase activity by approximately 40%. **C:** Aortas (aortic arch to the iliac bifurcation) from control and allosamidin-treated mice fed the atherogenic diet for 6 weeks were opened and stained *en face* with Oil Red O (Sigma-Aldrich). Representative images of the aortas showing the surface plaque (top) and quantification of surface area occupied by lesions in the aortic arch (bottom left) and the descending aortas (bottom right) are shown. Data (percentage of area occupied by lesions) are expressed as means  $\pm$  SEM for each group. **D:** Aortic sinus atherosclerosis in control and allosamidin-treated mice. Atherosclerotic lesion in the aortic sinus from cryosections was stained with Oil Red O and counterstained with H&E. Sections were also stained with Mac-3 or CD4 antibody coupled with horseradish peroxidase-labeled secondary antibody and counterstained with hematoxylin to identify the macrophages and T lymphocytes present in the aortic sinus lesions. Representative images for each staining are shown. The atherosclerotic lesion area stained with Oil Red O and the macrophage infiltration area stained with Mac-3 antibody were quantitated using a computer-assisted imaging system. \* $P < 0.05$ .

phenotype and T helper-2 response. In agreement with this, our data show that allosamidin treatment increased the expression of M1 markers and decreased the classic M2 marker, suggesting that CHIT1 polarizes macrophages into the anti-atherosclerotic M2 phenotype.

Cholesterol homeostasis within macrophages is determined by the balance between the uptake of modified lipids via the scavenger receptors SR-A and CD36, and cholesterol efflux via the reverse cholesterol transporters ABCA1 and ABCG1. Overexpression of human SR-A in bone marrow cells attenuated atherosclerosis in low density lipoprotein receptor-deficient or ApoE-deficient mice,<sup>31,32</sup> whereas SR-A deficiency in atherogenic apoE3-Leiden mice led to more severe and complex atherosclerotic lesions.<sup>33</sup> Loss of lipid uptake via SR-A or CD36 may lead to the formation of necrotic core within atherosclerotic lesions.<sup>34</sup> These reports suggest that lipid uptake via scavenger receptors may be protective against atherosclerosis. ABCA1 and ABCG1 mediate the critical part of cholesterol efflux from lipid-laden macrophages to HDL cholesterol.<sup>35,36</sup> Patients with Tangier disease (due to loss of

functional mutations in the ABCA1 gene) show low serum HDL cholesterol level, and have a moderately increased risk for coronary artery diseases.<sup>37,38</sup> Similarly, deficiency of either ABCA1 or ABCG1 in atherogenic hyperlipidemic mice led to massive lipid accumulation in macrophages and increased atherosclerotic lesions,<sup>39,40</sup> suggesting that cholesterol efflux via ABC transporters is anti-atherogenic. In our study, allosamidin treatment led to decreased SR-AI,

**Table 2** Various Measurements in Mice Treated with Allosamidin versus Control Mice

	Control	Allosamidin
<i>n</i>	6	6
Body weight, g	36.9 $\pm$ 1.2	35.8 $\pm$ 2.4
BP, mmHg	115/67 $\pm$ 4.8/8.3	115/71 $\pm$ 5.2/9.9
HR, bpm	588 $\pm$ 47	597 $\pm$ 44
Plasma total cholesterol, mg/dL	908.6 $\pm$ 76.8	929.8 $\pm$ 114.4
Plasma total triglycerides, mg/dL	134.0 $\pm$ 34.1	140.4 $\pm$ 38.1

No measurements were statistically significant.

CD36, ABCA1, and ABCG1 expression, which presumably resulted in suppressed cholesterol uptake and efflux from macrophages, leading to exacerbation of atherosclerosis.

Although a detailed molecular mechanism of the effects of CHIT1 is not fully elucidated in this study, its effects on immune response and cholesterol metabolism appear to involve the PPAR $\gamma$ -LXR $\alpha$  pathway. PPAR $\gamma$  has anti-inflammatory properties via negative interference with NF- $\kappa$ B, AP-1, and signal transducer and activator of transcription.<sup>41</sup> Furthermore, positive correlation was observed between PPAR $\gamma$  expression and the M2 markers, such as CD206, CD36, and CC-chemokine 1.<sup>42–44</sup> Additionally, activation of PPAR $\gamma$  and/or LXR $\alpha$  upregulates ABCA1 and ABCG1 expression,<sup>35,45</sup> and PPAR $\gamma$  agonists curb atherosclerosis by inhibiting foam cell formation.<sup>46</sup> Because our data show that expression of PPAR $\gamma$  and LXR $\alpha$  is decreased by allosamidin treatment, it is likely that CHIT1 exerts its anti-inflammatory effects and promotes cholesterol efflux from macrophages via activation of the PPAR $\gamma$ -LXR $\alpha$  pathway. The detailed mechanism of PPAR $\gamma$  and LXR $\alpha$  upregulation by CHIT1 is currently being investigated.

Whereas serum CHIT1 activity is reported to increase in patients with atherosclerosis and is correlated with the severity of the disease,<sup>4,5,15</sup> at least in the Corsica Island case-control study of patients with coronary artery disease and healthy subjects showed that the frequency of loss of function mutation in *CHIT1* gene is not correlated with the disease.<sup>47</sup> Similarly, because the range of serum CHIT1 activity values from control subjects is wide and in many cases overlaps with those from atherosclerosis patients,<sup>5</sup> it seems that these data do not necessarily indicate that *CHIT1* is just a marker of atherosclerosis. Further clinical studies are required to elucidate the physiological role of CHIT1 in human atherosclerotic diseases.

There are several limitations in interpreting our study to speculate CHIT1 functions in atherosclerosis. First, allosamidin is a pseudotrisaccharide consisting of two  $\beta$ <sup>1,4</sup>-linked *N*-acetyl allosamine sugars coupled to allosamizoline, which renders it an effective inhibitor of all members of the chitinase family 18.<sup>6,48</sup> Thus, another human chitinase, acidic mammalian chitinase, as well as family 18 chitinase-like mammalian proteins without chitinase activity, such as YM1 and gp-39, were likely inhibited by allosamidin in our *in vivo* study. Because expression of gp-39 is also reported to be strongly upregulated in macrophages in atherosclerotic lesions,<sup>4</sup> it is possible that allosamidin aggravated atherosclerotic lesions partly by inhibiting gp-39 function. Also, due to limitations in allosamidin delivery, atherosclerosis examined in the current study was not very advanced.

In summary, continuous administration of a chitinase inhibitor, allosamidin, for 6 weeks increased atherosclerotic lesions in hyperlipidemic mice. Allosamidin treatment caused increased expression of pro-inflammatory cytokines, including TNF $\alpha$  and MCP-1, induced M1 macrophage polarization, and decreased lipid uptake and cholesterol efflux in macrophages via down-regulation of SR-AI, CD36,

ABCA1, and ABCG1 expression. These data suggest that CHIT1 has a protective role against atherosclerosis, and that measures taken to enhance the local chitinase activity in atherosclerotic lesions may provide a novel treatment for atherosclerosis.

## Supplemental Data

Supplemental material for this article can be found at <http://dx.doi.org/10.1016/j.ajpath.2013.04.003>.

## References

- Libby P, Ridker PM, Hansson GK: Progress and challenges in translating the biology of atherosclerosis. *Nature* 2011, 473:317–325
- Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT: Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. *Circulation* 1994, 90:775–778
- Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, Hrebicek M, Aerts JM: Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. *Eur J Biochem* 1998, 251:504–509
- Boot RG, van Achterberg TA, van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, de Vries CJ: Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. *Arterioscler Thromb Vasc Biol* 1999, 19:687–694
- Artieda M, Cenarro A, Gañán A, Jericó I, Gonzalvo C, Casado JM, Vitoria I, Puzo J, Pocióvi M, Civeira F: Serum chitotriosidase activity is increased in subjects with atherosclerosis disease. *Arterioscler Thromb Vasc Biol* 2003, 23:1645–1652
- Sakuda S, Isogai A, Matsumoto S, Suzuki A: Search for microbial insect growth regulators. II Allosamidin, a novel insect chitinase inhibitor. *J Antibiot (Tokyo)* 1987, 40:296–300
- Schiller NK, Black AS, Bradshaw GP, Bonnet DJ, Curtiss LK: Participation of macrophages in atherosclerotic lesion morphology in LDLr<sup>-/-</sup> mice. *J Lipid Res* 2004, 45:1398–1409
- Kuranda MJ, Robbins PW: Chitinase is required for cell separation during growth of *Saccharomyces cerevisiae*. *J Biol Chem* 1991, 266:19758–19767
- Ricci R, Sumara G, Sumara I, Rozenberg I, Kurrer M, Akhmedov A, Hersberger M, Eriksson U, Eberli FR, Becher B, Boren J, Chen M, Cybulsky MI, Moore KJ, Freeman MW, Wagner EF, Matter CM, Luscher TF: Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. *Science* 2004, 306:1558–1561
- Matsushima Y, Sakurai T, Ohoka A, Ohnuki T, Tada N, Asoh Y, Tachibana M: Four strains of spontaneously hyperlipidemic (SHL) mice: phenotypic distinctions determined by genetic backgrounds. *J Atheroscler Thromb* 2001, 8:71–79
- Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroute H, Curtiss LK, Berliner JA, Boisvert WA: Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. *Circ Res* 2002, 90:1064–1071
- Kitamoto S, Nakano K, Hirouchi Y, Kohjimoto Y, Kitajima S, Usui M, Inoue S, Egashira K: Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by anti-monocyte chemoattractant protein-1 therapy in nonhuman primates. *Arterioscler Thromb Vasc Biol* 2004, 24:1522–1528
- Di Rosa M, Musumeci M, Scuto A, Musumeci S, Malaguarnera L: Effect of interferon-gamma, interleukin-10, lipopolysaccharide and tumor necrosis factor-alpha on chitotriosidase synthesis in human macrophages. *Clin Chem Lab Med* 2005, 43:499–502

14. Zhu Z, Zheng T, Homer RJ, Kim Y-K, Chen NY, Cohn L, Hamid Q, Elias JA: Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. *Science* 2004, 304:1678–1682
15. Karadag B, Kucur M, Isman FK, Hacibekiroglu M, Vural VA: Serum chitotriosidase activity in patients with coronary artery disease. *Circ J* 2008, 72:71–75
16. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. *Circulation* 2002, 105:1135–1143
17. Artieda M, Cenarro A, Ganan A, Lukic A, Moreno E, Puzo J, Pocovi M, Civeira F: Serum chitotriosidase activity, a marker of activated macrophages, predicts new cardiovascular events independently of C-reactive protein. *Cardiology* 2007, 108:297–306
18. Sotgiu S, Barone R, Zanda B, Arru G, Fois ML, Arru A, Rosati G, Marchetti B, Musumeci S: Chitotriosidase in patients with acute ischemic stroke. *Eur Neurol* 2005, 54:149–153
19. Hollak CE, van Weely S, van Oers MH, Aerts JM: Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. *J Clin Invest* 1994, 93:1288–1292
20. Brinkman J, Wijburg FA, Hollak CE, Groener JE, Verhoek M, Scheij S, Aten J, Boot RG, Aerts JM: Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann-Pick disease. *J Inherit Metab Dis* 2005, 28:13–20
21. Michelakakis H, Dimitriou E, Labadaridis I: The expanding spectrum of disorders with elevated plasma chitotriosidase activity: an update. *J Inherit Metab Dis* 2004, 27:705–706
22. Guo Y, He W, Boer AM, Wevers RA, de Bruijn AM, Groener JE, Hollak CE, Aerts JM, Galjaard H, van Diggelen OP: Elevated plasma chitotriosidase activity in various lysosomal storage disorders. *J Inherit Metab Dis* 1995, 18:717–722
23. Malaguamera L, Musumeci M, Di Rosa M, Scuto A, Musumeci S: Interferon-gamma, tumor necrosis factor-alpha, and lipopolysaccharide promote chitotriosidase gene expression in human macrophages. *J Clin Lab Anal* 2005, 19:128–132
24. Fach EM, Garulacan L-A, Gao J, Xiao Q, Storm SM, Dubaquié YP, Hefta SA, Opitck GJ: In vitro biomarker discovery for atherosclerosis by proteomics. *Mol Cell Proteomics* 2004, 3:1200–1210
25. Tabas I: Macrophage death and defective inflammation resolution in atherosclerosis. *Nat Rev Immunol* 2010, 10:36–46
26. Mantovani A, Garlanda C, Locati M: Macrophage diversity and polarization in atherosclerosis: a question of balance. *Arterioscler Thromb Vasc Biol* 2009, 29:1419–1423
27. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariety J, Nicoletti A: In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. *Circulation* 2001, 104:197–202
28. Martinez FO, Helming L, Gordon S: Alternative activation of macrophages: an immunologic functional perspective. *Annu Rev Immunol* 2009, 27:451–483
29. Han X, Kitamoto S, Wang H, Boisvert WA: Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. *FASEB J* 2010, 24:2869–2880
30. Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD: Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. *Am J Clin Pathol* 2004, 122:359–369
31. Van Eck M, De Winther MP, Herijgers N, Havekes LM, Hofker MH, Groot PH, Van Berkel TJ: Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on cholesterol levels and atherosclerosis in ApoE-deficient mice. *Arterioscler Thromb Vasc Biol* 2000, 20:2600–2606
32. Herijgers N, de Winther MP, Van Eck M, Havekes LM, Hofker MH, Hoogerbrugge PM, Van Berkel TJ: Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knockout mice. *J Lipid Res* 2000, 41:1402–1409
33. de Winther MP, Gijbels MJ, van Dijk KW, van Gorp PJ, Suzuki H, Kodama T, Frants RR, Havekes LM, Hofker MH: Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3-Leiden transgenic mice. *Atherosclerosis* 1999, 144:315–321
34. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM, McKee M, Freeman MW: Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. *J Clin Invest* 2005, 115:2192–2201
35. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA: ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. *Cell Metab* 2005, 1:121–131
36. Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, Cain WJ, Fruchart-Najib J, Neufeld ED, Remaley AT, Brewer HB Jr, Santamarina-Fojo S: ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. *J Clin Invest* 2001, 108:303–309
37. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Deneffe P, Assmann G: Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. *Nat Genet* 1999, 22:352–355
38. Serfaty-Lacrosniere C, Civeira F, Lanzberg A, Isaia P, Berg J, Janus ED, Smith MP Jr., Pritchard PH, Frohlich J, Lees RS, Barnard GF, Ordovas JM, Schaefer EJ: Homozygous Tangier disease and cardiovascular disease. *Atherosclerosis* 1994, 107:85–98
39. van Eck M, Bos IS, Kaminski WE, Orso E, Rothe G, Twisk J, Bottcher A, Van Amersfoort ES, Christiansen-Weber TA, Fung-Leung WP, Van Berkel TJ, Schmitz G: Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. *Proc Natl Acad Sci USA* 2002, 99:6298–6303
40. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, Coskran T, Haghpassand M, Francone OL: Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. *Arterioscler Thromb Vasc Biol* 2002, 22:630–637
41. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. *Inflamm Res* 2000, 49:497–505
42. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM: PPAR-gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. *Cell* 1998, 93:241–252
43. Coste A, Dubourdeau M, Linas MD, Cassaing S, Lepert JC, Balard P, Chalmeton S, Bernad J, Orfila C, Seguela JP, Pipy B: PPARgamma promotes mannose receptor gene expression in murine macrophages and contributes to the induction of this receptor by IL-13. *Immunity* 2003, 19:329–339
44. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G: PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. *Cell Metab* 2007, 6:137–143
45. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P: A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. *Mol Cell* 2001, 7:161–171
46. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Villedor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. *J Clin Invest* 2004, 114:1564–1576
47. Piras I, Falchi A, Melis A, Ghiani ME, Calo CM, Varesi L, Vona G: 24 bp duplication of CHIT1 gene is not correlated with coronary artery disease in Corsica Island, (France). *Exp Mol Pathol* 2007, 83:490–492
48. Fusetti F, von Moeller H, Houston D, Rozeboom HJ, Dijkstra BW, Boot RG, Aerts JMFG, van Aalten DMF: Structure of human chitotriosidase. Implications for specific inhibitor design and function of mammalian chitinase-like lectins. *J Biol Chem* 2002, 277:25537–25544